DK0723540T3 - Tricykliske amid- og urinstofderivater til inhibering af funktion af G-protein og til behandling af proliferative sygdomme - Google Patents

Tricykliske amid- og urinstofderivater til inhibering af funktion af G-protein og til behandling af proliferative sygdomme

Info

Publication number
DK0723540T3
DK0723540T3 DK94930650T DK94930650T DK0723540T3 DK 0723540 T3 DK0723540 T3 DK 0723540T3 DK 94930650 T DK94930650 T DK 94930650T DK 94930650 T DK94930650 T DK 94930650T DK 0723540 T3 DK0723540 T3 DK 0723540T3
Authority
DK
Denmark
Prior art keywords
inhibition
treatment
proliferative diseases
protein function
urea derivatives
Prior art date
Application number
DK94930650T
Other languages
Danish (da)
English (en)
Inventor
Alan K Mallams
W Robert Bishop
Ronald J Doll
F George Njoroge
Joanne M Petrin
John J Piwinski
Stacy W Remiszewski
Arthur G Taveras
Ronald L Wolin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22479374&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0723540(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK0723540T3 publication Critical patent/DK0723540T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK94930650T 1993-10-15 1994-10-12 Tricykliske amid- og urinstofderivater til inhibering af funktion af G-protein og til behandling af proliferative sygdomme DK0723540T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13786293A 1993-10-15 1993-10-15
PCT/US1994/011392 WO1995010516A1 (en) 1993-10-15 1994-10-12 Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
DK0723540T3 true DK0723540T3 (da) 2002-03-25

Family

ID=22479374

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94930650T DK0723540T3 (da) 1993-10-15 1994-10-12 Tricykliske amid- og urinstofderivater til inhibering af funktion af G-protein og til behandling af proliferative sygdomme

Country Status (20)

Country Link
EP (2) EP1123931B1 (es)
JP (1) JP2880576B2 (es)
AT (2) ATE296819T1 (es)
AU (2) AU700246B2 (es)
CA (1) CA2174104C (es)
DE (2) DE69434397T2 (es)
DK (1) DK0723540T3 (es)
ES (2) ES2240270T3 (es)
HK (1) HK1039488B (es)
HU (1) HUT76056A (es)
IL (1) IL111235A (es)
MA (1) MA23354A1 (es)
MY (1) MY114132A (es)
NZ (2) NZ329374A (es)
PT (1) PT723540E (es)
SG (1) SG75084A1 (es)
TN (1) TNSN94106A1 (es)
TW (1) TW334432B (es)
WO (1) WO1995010516A1 (es)
ZA (1) ZA947971B (es)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0703905A1 (en) * 1993-06-18 1996-04-03 Merck & Co. Inc. Inhibitors of farnesyl-protein transferase
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US5700806A (en) * 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5856326A (en) * 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
IL117797A0 (en) * 1995-04-07 1996-08-04 Pharmacopeia Inc Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
AU6034296A (en) * 1995-06-16 1997-01-15 Warner-Lambert Company Tricyclic inhibitors of protein farnesyltransferase
WO1997002817A1 (en) * 1995-07-13 1997-01-30 University Of Cincinnati Compounds useful in the treatment of neurofibromatosis
SK86198A3 (en) * 1995-12-22 1999-02-11 Schering Corp Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
AU769687B2 (en) * 1995-12-22 2004-01-29 Merck Sharp & Dohme Corp. Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative diseases
WO1997027752A1 (en) * 1996-01-30 1997-08-07 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6117641A (en) 1996-04-11 2000-09-12 Mitotix, Inc. Assays and reagents for identifying anti-fungal agents and uses related thereto
JP2001513622A (ja) 1996-04-11 2001-09-04 マイトティックス インコーポレーテッド 抗菌剤の同定のためのアッセイおよび試薬、並びにそれらに関連する利用
US6727082B1 (en) 1996-04-11 2004-04-27 Gpc Biotech Inc. Assays and reagents for identifying anti-fungal agents, and uses related thereto
DE19624704A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalkansäureamide
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5925757A (en) * 1996-07-26 1999-07-20 Schering Corporation Method for preparing carboxamides
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
US6040305A (en) * 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
ATE294172T1 (de) * 1996-09-13 2005-05-15 Schering Corp Substituierte benzocycloheptapyridine derivate verwendbar als farnesyl-protein transferase inhibitoren
US5985879A (en) * 1996-09-13 1999-11-16 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
CZ83499A3 (cs) * 1996-09-13 1999-07-14 Schering Corporation Tricyklické sloučeniny, farmaceutický prostředek je obsahující a jejich použití
US6030982A (en) 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
ES2235252T3 (es) * 1996-09-13 2005-07-01 Schering Corporation Inhibidores triciclicos de la farnesil proteina transferasa.
US5965570A (en) * 1996-09-13 1999-10-12 Schering Corporation Tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
DE69732123T2 (de) * 1996-09-13 2005-12-08 Schering Corp. Trizyklische Verindung mit Farnesylproteintransferase inhibierender Wirkung
US5958890A (en) * 1996-09-13 1999-09-28 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
KR20000068550A (ko) * 1996-09-13 2000-11-25 쉐링 코포레이션 파르네실 단백질 전이효소의 억제에 유용한 화합물
SK33599A3 (en) * 1996-09-13 2000-03-13 Schering Corp Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase
ES2229340T3 (es) * 1996-09-13 2005-04-16 Schering Corporation Compuestos triciclicos antitumorales, inhibidores de farnesil-proteina-tranferasa.
CA2265764A1 (en) * 1996-09-13 1998-03-19 Schering Corporation Tricyclic compounds useful as fpt inhibitors
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
CN1237170A (zh) * 1996-09-13 1999-12-01 先灵公司 用作法呢基蛋白转移酶抑制剂的新的三环哌啶基化合物
US5994364A (en) * 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
US5945429A (en) * 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
BR9712825A (pt) * 1996-09-13 1999-11-23 Schering Corp Derivados de benzocicloheptaridina substituìdos úteis para a inibição de transferase de proteìna de farnesila.
US6130229A (en) * 1996-10-09 2000-10-10 Schering Corporation Tricyclic compounds having activity as RAS-FPT inhibitors
US5972966A (en) * 1996-12-05 1999-10-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5898810A (en) * 1997-04-04 1999-04-27 Minnesota Mining And Manufacturing Company Illumination waveguide and method for producing same
US5760232A (en) * 1997-06-16 1998-06-02 Schering Corporation Synthesis of intermediates useful in preparing bromo-substituted tricyclic compounds
JP2002504150A (ja) * 1997-06-17 2002-02-05 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼの新規フェニル置換三環式インヒビター
US6689789B2 (en) 1997-06-17 2004-02-10 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
DE69825589T2 (de) * 1997-06-17 2005-09-08 Schering Corp. Benzpyrido cycloheptan derivate mit farnesyl protein transferase inhibierender wirkung
CN1286690A (zh) * 1997-06-17 2001-03-07 先灵公司 用于抑制法尼基蛋白转移酶的化合物
US6358968B1 (en) 1997-06-17 2002-03-19 Schering Corporation N-substituted urea inhibitors of farnesyl-protein transferase
WO1998057961A1 (en) * 1997-06-17 1998-12-23 Schering Corporation Bispyrido-cycloheptane compounds useful for inhibition of farnesyl protein transferase
US6159984A (en) 1997-06-17 2000-12-12 Schering Corporation Farnesyl protein transferase inhibitors
JP2002510308A (ja) * 1997-06-17 2002-04-02 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼインヒビターとしてのベンゾ（５，６）シクロヘプタ（１，２−ｂ）ピリジン誘導体
JP2002504151A (ja) * 1997-06-17 2002-02-05 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼの新規アミノオキシアミド三環式インヒビター
US6218401B1 (en) 1997-06-17 2001-04-17 Schering Corporation Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
US5852034A (en) * 1997-06-17 1998-12-22 Schering Corporation Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors
US5945430A (en) * 1997-06-17 1999-08-31 Schering Corporation Aminooxyamide tricyclic inhibitors of farnesyl-protein transferase
US6225322B1 (en) 1997-06-17 2001-05-01 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
WO1998057964A1 (en) * 1997-06-17 1998-12-23 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
CA2294347C (en) * 1997-06-17 2008-01-29 Schering Corporation Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives for the inhibition of farnesyl protein transferase
US6051582A (en) * 1997-06-17 2000-04-18 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6228865B1 (en) 1997-06-17 2001-05-08 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6576639B1 (en) 1997-06-17 2003-06-10 Schering Corporation Compounds for the inhibition of farnesyl protein transferase
US5939416A (en) * 1997-06-17 1999-08-17 Schering Corporation Benzo (5,6) cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors
IL133392A0 (en) * 1997-06-17 2001-04-30 Schering Corp Benzo (5, 6) cyclohepta (1, 2b) pyridine derivatives useful for inhibition of farnesyl protein transferase
US5877177A (en) * 1997-06-17 1999-03-02 Schering Corporation Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
WO1998057948A1 (en) * 1997-06-17 1998-12-23 Schering Corporation Novel n-substituted urea inhibitors of farnesyl-protein transferase
NZ501615A (en) * 1997-06-17 2002-02-01 Schering Corp Benzo[5,6]cyclohepta[1,2-b] pyridine derivatives useful for inhibition of farnesyl protein transferase
US6211193B1 (en) 1997-06-17 2001-04-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6037166A (en) * 1997-06-17 2000-03-14 Schering Corporation Enzymatic kinetic resolution of an intermediate useful for preparing substituted tricyclics
US5925639A (en) * 1997-06-17 1999-07-20 Schering Corporation Keto amide derivatives useful as farnesyl protein transferase inhibitors
US6239140B1 (en) 1997-06-17 2001-05-29 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
US5958940A (en) * 1997-09-11 1999-09-28 Schering Corporation Tricyclic compounds useful as inhibitors of farnesyl-protein transferase
DE19756212A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
US6903118B1 (en) 1997-12-17 2005-06-07 Klinge Pharma Gmbh Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
US6307048B1 (en) 1998-11-20 2001-10-23 Schering Corporation Enantioselective alkylation of tricyclic compounds
BR9916328A (pt) * 1998-12-18 2001-10-02 Schering Corp Inibidores de transferase de farnesila
US6800636B2 (en) 1998-12-18 2004-10-05 Schering Corporation Farnesyl protein transferase inhibitors
US6372747B1 (en) 1998-12-18 2002-04-16 Schering Corporation Farnesyl protein transferase inhibitors
US6362188B1 (en) 1998-12-18 2002-03-26 Schering Corporation Farnesyl protein transferase inhibitors
CN1326850C (zh) 1998-12-18 2007-07-18 先灵公司 三环类法尼基蛋白转移酶抑制剂
EP1031564A1 (en) 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
WO2002042284A1 (fr) * 2000-11-22 2002-05-30 Pola Chemical Industries, Inc. Derives de piperazine dibenzosuberanyle et agents surmontant la resistance aux medicaments contenant ces derives
CA2429720C (en) * 2000-11-29 2009-12-29 Schering Corporation Tricyclic compounds useful for the inhibition of farnesyl protein transferase
US6645966B2 (en) * 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
US6703400B2 (en) 2001-02-23 2004-03-09 Schering Corporation Methods for treating multidrug resistance
EP1443936A4 (en) 2001-11-13 2006-01-11 Bristol Myers Squibb Co PROCESS FOR THE PREPARATION OF 3,7-DISUBSTITUE-2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPINE COMPOUNDS
TW200510396A (en) 2003-06-25 2005-03-16 Schering Corp Metabolites of tricyclic amides useful for inhibition of g-protein function and methods of treatment of proliferative diseases
KR20060057599A (ko) * 2003-08-07 2006-05-26 쉐링 코포레이션 항종양제로서 신규한 파르네실 단백질 트랜스퍼라제 억제제
US7417026B2 (en) 2003-08-13 2008-08-26 Children's Hospital Medical Center Mobilization of hematopoietic cells
CA2590979A1 (en) 2004-12-13 2006-06-22 Schering Corporation Novel farnesyl protein transferase inhibitors and their use to treat cancer
US20060205755A1 (en) * 2004-12-21 2006-09-14 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
MX2008013427A (es) 2006-04-19 2008-11-04 Novartis Ag Compuestos de benzoxazole y benzotiazole sustituidos-6-0 y metodos para inhibir la señalizacion csf-1r.
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
MX2009007200A (es) 2007-01-10 2009-07-15 Angeletti P Ist Richerche Bio Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp).
EP2132177B1 (en) 2007-03-01 2013-07-17 Novartis AG Pim kinase inhibitors and methods of their use
EP2152700B1 (en) 2007-05-21 2013-12-11 Novartis AG Csf-1r inhibitors, compositions, and methods of use
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合複素環式化合物およびそれらの使用
EA023838B1 (ru) 2009-10-14 2016-07-29 Мерк Шарп Энд Домэ Корп. ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
CA2791613A1 (en) 2010-03-16 2011-09-22 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2807307C (en) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
AU2012245971A1 (en) 2011-04-21 2013-10-17 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
AU2012340200B2 (en) 2011-11-17 2017-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-Terminal Kinase (JNK)
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
WO2014025852A1 (en) * 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Tricyclic alkene derivatives as hiv attachment inhibitors
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
ME02925B (me) 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
CN104418836A (zh) * 2013-09-09 2015-03-18 天津药物研究院 双酰胺类化合物及其制备方法和用途
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
EP3236959A4 (en) 2014-12-23 2018-04-25 Dana Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
EP3609922A2 (en) 2017-04-13 2020-02-19 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
IL292616A (en) * 2019-10-31 2022-07-01 Jd Bioscience Inc Tricyclic compounds, preparations containing them and their uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826853A (en) * 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
CA2098198A1 (en) * 1990-12-18 1992-06-18 Ann Christie King Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
JPH0676403B2 (ja) * 1991-01-18 1994-09-28 エスエス製薬株式会社 新規なベンゾ［５，６ シクロヘプタ［１，２−ｂ ピリジン誘導体及びこれを含有する抗アレルギー剤

Also Published As

Publication number Publication date
IL111235A (en) 2001-03-19
EP1123931B1 (en) 2005-06-01
AU700246B2 (en) 1998-12-24
IL111235A0 (en) 1994-12-29
NZ275647A (en) 1999-08-30
CA2174104A1 (en) 1995-04-20
MA23354A1 (fr) 1995-07-01
ATE296819T1 (de) 2005-06-15
MY114132A (en) 2002-08-30
EP0723540A1 (en) 1996-07-31
TW334432B (en) 1998-06-21
DE69429441T2 (de) 2002-08-29
AU9239998A (en) 1999-02-04
EP1123931A1 (en) 2001-08-16
HK1039488A1 (en) 2002-04-26
HK1039488B (zh) 2005-11-11
DE69429441D1 (de) 2002-01-24
TNSN94106A1 (fr) 1995-09-21
ES2164718T3 (es) 2002-03-01
PT723540E (pt) 2002-05-31
ZA947971B (en) 1996-07-12
HU9600962D0 (en) 1996-06-28
ATE210654T1 (de) 2001-12-15
JPH08510760A (ja) 1996-11-12
AU735262B2 (en) 2001-07-05
EP0723540B1 (en) 2001-12-12
WO1995010516A1 (en) 1995-04-20
DE69434397T2 (de) 2006-04-27
JP2880576B2 (ja) 1999-04-12
DE69434397D1 (de) 2005-07-07
ES2240270T3 (es) 2005-10-16
SG75084A1 (en) 2000-09-19
NZ329374A (en) 1999-07-29
AU7970394A (en) 1995-05-04
HUT76056A (en) 1997-06-30
CA2174104C (en) 2004-01-20

Similar Documents

Publication Publication Date Title
DK0723540T3 (da) Tricykliske amid- og urinstofderivater til inhibering af funktion af G-protein og til behandling af proliferative sygdomme
DK0723538T3 (da) Tricykliske carbamatforbindelser, der er nyttige til inhibition af funktion af G-protein og til behandling af proliferative sygdomme
HU9600957D0 (en) Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
CA2216163A1 (en) Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
MX9707665A (es) Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para el tratamiento de enfermedades proliferativas.
IL117799A0 (en) Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
MX9707197A (es) Compuestos triciclicos de urea que son utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proliferativas.
ATE220400T1 (de) Trizyklische verbindungen zur behandlung von zellproliferativen störungen
ATE237611T1 (de) Cyclische harnstoff- und lactamderivate von benzo(5,6)cycloheptapyridinen zur verwendung als farnesyl-protein-transferase-hemmer